Takeaway
- None of the 3 medications commonly used to treat fatigue in patients with multiple sclerosis (MS) were significantly more efficacious than placebo.
Why this matters
- More than three-quarters of patients with MS experience fatigue, and more than half report it as their worst symptom.
Key results
- Estimated mean Modified Fatigue Impact Scale total score:
- 51.3 at baseline,
- 40.6 with placebo,
- 41.3 with amantadine,
- 39.0 with modafinil, and
- 38.6 with methylphenidate.
- No significant difference for overall medication effect (P=.20).
- Similar results for:
- QoL in Neurological Disorders fatigue T score (P=.42).
- Epworth Sleepiness Scale score (P=.071).
- Adverse event rates:
- 31% with placebo,
- 39% with amantadine,
- 40% with modafinil, and
- 40% with methylphenidate.
- 3 serious adverse events:
- Pulmonary embolism and myocarditis on amantadine.
- MS exacerbation requiring hospitalization on modafinil.
Study design
- US phase 3, randomized controlled crossover trial (TRIUMPHANT-MS).
- 3 medications vs placebo in 141 adult patients with MS and fatigue.
- Randomization: 4 sequences of medication administration.
- Main outcome: Modified Fatigue Impact Scale score at highest tolerated dose (week 5) of each treatment period.
- Funding: Patient-Centered Outcomes Research Institute.
Limitations
- Unknown generalizability.
- Each treatment period was short (6 weeks).
- Adherence was not monitored.
- Limited power for subgroup analyses.
Dieser Volltext ist leider reserviert für Angehöriger medizinischer Fachkreise
Sie haben die Maximalzahl an Artikeln für unregistrierte besucher erreicht
Kostenfreier Zugang Nur für Angehörige medizinischer Fachkreise